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Abstract 
Primary Oral Mucosal Melanoma (POMM) is an 
aggressive and rare disease that involves mostly the 
hard palate and upper gingiva, followed by 
mandibular gingiva, lip mucosa, and other oral sites. 
POMM develops primarily between the 5th and 8th 
decades of life and most studies report a similar 
distribution between males and females. In contrast 
to cutaneous melanomas, the risk factors and 
pathogenesis are poorly understood. However, 
genetic profiling of mucosal melanomas have 
identified a number of altered genes, such as KIT, 
BRAF and N-RAS, suggesting that molecular 
pathways like the mitogen-activated protein kinase 
(MAPK) pathway (RAS/MEK/ERK) and the 
phosphotidylinositol-3-kinase-PTEN pathway 
(PI3K/AKT/PTEN/mTOR) might be used for 
potential targeted therapy. 
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Classification 
Mucosal melanoma of Head and Neck (MMHN) 
have been classified as stage I, disease confined to 
the primary site; stage II, regional lymph node 
metastasis; and stage III, distant metastasis 
(Ballantyne, 1970). Most patients will present with 
localized (stage I) disease and this classification 
offers limited prognostic information. Prasad et al. 
(2004) proposed a classification system based on the 
level of invasion: level 1, in situ melanoma; level 2, 
superficially invasive; and level 3, deeply invasive. 
The American Joint Committee on Cancer (AJCC) 
published a dedicated staging system for MMHN 
based on the tumor, node, metastasis (TNM) 
classification similar to the staging system for 
cutaneous melanoma (Edge et al., 2010) (Table 1); 
however, primary MMHN limited to the mucosa are 
considered T3 lesions to reflect their aggressive 
behavior (Tacastacas et al., 2014; Warszawik-
Hendzel et al., 2014).  
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Table 1. Classification for the mucosal melanoma of the head and neck - AJCC Cancer Staging Manual 7th edition (2010) - T3-
T4a / N1 / M0 
 
Clinics and pathology 
Etiology 
The etiopathogenesis of mucosal melanomas is not 
yet established. Sun exposure is not related to its 
genesis. However, ethnicity, family history, 
syndromes and preexisting lesions may influence its 
development (Batsakis et al., 1982; Lopez et al., in 
press; Warszawik-Hendzel et al., 2014). 
Epidemiology 
POMM is rare and represents 0.2 to 8.0% of all 
melanomas diagnosed in Europe and United States 
and 0.26% of all oral cavity tumors (McLaughlin et 
al., 2005; Chidzonga et al., 2007; Sortino-Rachou et 
al., 2009). Most studies report a similar distribution 
of mucosal melanomas (MM) between males and 
females. However, there is a significant discrepancy 
in the incidence of MMHN between races: among 
Japanese oral melanoma accounts for 7.5% of all 
melanomas versus less than 1% in Caucasians. MM 
develops primarily between the 5th and 8th decades 
of life and the incidence increases with age 
(L&oacute;pez et al., in press; Warszawik-Hendzel 
et al., 2014; Louren&ccedil;o et al., 2014; 
Mihajlovic et al., 2012; Meleti et al., 2007). 
Clinics 
POMM involves mostly the hard palate and upper 
gingiva, followed by mandibular gingiva, lip 
mucosa, and other oral sites. Image exams are 
mandatory to confirm that oral mucosa is the primary 
site of the lesion. Clinically, POMM lesions may be 
macular or nodular and they can appear as black, 
brown, white, gray, purple, or reddish shades. 
Satellite lesions are frequently present surrounding 
the initial tumor.  Approximately a third of all oral 
melanomas are asymptomatic (Warszawik-Hendzel 
et al., 2014; Louren&ccedil;o et al., 2014). POMM 
lesions are usually found during routine dental 
examination. Alternatively, symptoms may include 
complaints of ill-fitting dentures, ulceration, and 
bleeding (Patel et al., 2002; Rapidis et al., 2003; 
Gavriel et al., 2010). In Figure 1, an example of oral 
mucosal melanoma can be observed. 
 
Figure 1. Primary oral mucosal melanoma affecting the 
lower gingival and lip mucosa. 
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Pathology 
Usually mucosal melanomas can be diagnosed with 
confidence on H&E stained sections. In case of 
amelanotic lesions, immunohistochemical stains are 
of significant help.  
Useful markers include S-100 protein, HMB-45, and 
Melan-A (Meleti et al., 2007; Lourenço et al., 2014).  
Histologically, POMM is characterized by the 
proliferation of neoplastic melanocytes with variable 
phenotypes epithelioid, spindle, and plasmacytoid 
tumor cells that are arranged in a sheet-like, 
organoid, alveolar, solid, or desmoplastic 
architecture.  
Tumors with mixed cell phenotypes are more 
aggressive and are associated with a higher 
prevalence of vascular invasion and metastasis. 
Usually the neoplastic proliferation lies along the 
junction between the epithelial and lamina propria, 
but in advanced, ulcerated lesions, this might be 
difficult to be detected.  
Melanin pigment is noted in almost 90% of lesions. 
The Clark and Breslow classifications are the most 
frequently used assessment systems for the 
prognosis of cutaneous melanoma, but they less 
applicable in the oral cavity due of its histological 
peculiarity.  
In 1995, the Western Society of Teachers of Oral 
Pathology agreed that POMM lesions should be 
considered separately from the cutaneous form. 
There are 3 histological stages of POMMs: stage 1, 
primary site; stage 2, with lymph node metastasis; 
and stage 3, with distant metastasis.  
Furthermore, a 3-level microstage system was 
established: level 1, in situ melanoma with no 
evidence of invasion or with the presence of 
individual or agglomerated invasive melanocytes 
with fewer than 10 atypical melanocytes near the 
subepithelial junction; level 2, melanoma cells, 
limited to the lamina propria; and level 3, invasion 
of the deep conjunctive tissue, including skeletal 
muscle, bone, or cartilage.  
There are yet several issues that must be addressed 
in the histological evaluation of head and neck 
PMMs: (1) the architecture of the lesion in small 
biopsies, (2) difficulties in specimen representation, 
and (3) advanced disease stage that might be 
associated with tumor necrosis.  
Histopathological aspects of mucosal melanomas 
can be observed in Figures 2, 3 and 4. 
Treatment 
The mainstay treatment for mucosal melanoma is 
complete surgical resection. In patients with 
recurrent disease and without distant disease, a 
second surgical procedure is considered as the best 
option (Lopez et al., in press).  
Although malignant melanoma has been regarded as 
a radioresistant tumor, radiotherapy has become 
utilized as adjuvant treatment, considering the tumor 
heterogeneity.  
Precise indications for radiotherapy have not been 
defined and it is generally used only in advanced and 
recurrent cases (Krengli et al., 2008; Wagner et al., 
2008).  
So far, no systemic therapy has been recognized as 
effective for metastatic mucosal melanoma of the 
head and neck. Combinations of cytotoxic 
chemotherapy with immunotherapy have shown 
higher response rates (Bartell et al., 2008). Some 
targeted therapies have been considered as effective 
for patients with c-Kit or BRAF gene mutations 
(Lopez et al., in press; Warszawik-Hendzel et al., 
2014). 
Prognosis 
Mucosal melanoma of the head and neck has a poor 
prognosis with few long-term survivors. 
Undifferentiated tumor cell morphology, vascular 
and neural invasion, tumor necrosis, thickness of the 
tumor, cervical lymph node metastasis are 
considered to be independent predictors of outcome 
(Lopez et al., in press; Kerr et al., 2012; Prasad et al., 
2002). Five-year survival rate have been reported to 
be within the range of 4.5 to 48.0% (Shuman et al., 
2011; Gonzalez-Garcia et al., 2005; Rapidis et al., 
2003). Prasad et al. (2012) investigating molecular 
predictors of prognosis in mucosal melanomas 
reported that Bcl-2 expression is associated with 
better survival. Other factors associated with poor 
prognosis are loss of p16 expression and positivity 
for p53, although these results did not reach 
statistical significance. 
Embryonic origin 
The cell of origin of Primary Oral Mucosal 
Melanoma (POMM) is the melanocyte, which are 
cells derived from the neural crest and that migrate 
to endodermal or ectodermal derived tissues, 
including mucosa (Barrett & Raja, 1997; Batsakis, 
1999). 
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Figure 2. Primary oral mucosal melanoma (level I):  neoplastic nests at the epithelial/lamina propria junction. (H&E, original 
magnification X400) 
 
 
 
 
Figure 3 Primary oral mucosal melanoma (level II): invasive melanoma with neoplastic cells detected in the lamina propria. 
(H&E, original magnification X400) 
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Figure 4. Primary oral mucosal melanoma (level III): deeply invasive melanoma up to the bone structures. (H&E, original 
magnification X400) 
 
Genetics 
There are some signaling pathways involved in 
mucosal melanoma pathogenesis.  
The mitogen-activated protein kinase (MAPK) 
pathway (RAS/MEK/ERK) is a critical growth 
cascade in oral mucosal melanoma. Another 
important pathway is the phosphotidylinositol-3-
kinase-PTEN pathway (PI3K/AKT/PTEN/mTOR), 
which is involved in the regulation of cell death. 
These two signaling pathways can be triggered by 
activation of c-kit (Soma et al., 2014; Kerr et al 2012; 
Buery et al., 2011; Junkins-Hopkins, 2010) (Figure 
5). C-KIT regulates the activity of MITF 
(microphthalmia-associated transcription factor) a 
transcription factor that is important for 
melanogenesis and melanocyte function. MITF 
expression has been found in 40 to 91% of mucosal 
melanomas of the head and neck (Morris et al., 2008; 
Prasad et al., 2001).  
High rates of c-kit protein expression has been 
reported for mucosal melanomas and this 
immunohistochemical expression is associated with 
c-kit mutation (Rivera et al., 2008).  
A review of the literature report that 14% of mucosal 
melanomas harbor activating C-KIT mutations; 5% 
showed BRAF mutation and 14% oncogenic 
mutations in NRAS, which is much lower than the 
reported BRAF prevalence (56 to 59%) in cutaneous 
melanomas (Tacastacas et al., 2014; Cohen et al., 
2004). Our group also investigated mutational status 
of NRAS and BRAF genes in oral mucosal 
melanoma: mutation in NRAS codons 12 and 13 was 
observed in 14.3% of the samples; NRAS codon 61 
mutation was observed in 25.0% of the samples and 
21.4% of the cases showed BRAF codon 600 
mutation (unpublished results). Prasad et al. (2004) 
reported that cancer-testis antigens (CT7, MAGE-
A4, and NY-ESO-1) are frequently expressed in 
HNMM and may be potential targets for CTA based 
immunotherapy. Gwosdz et al. (2006) examined by 
immunohistochemistry and sequence analysis of the 
entire coding region of the p53 transcript in mucosal 
melanomas. Accumulation of the p53 protein 
occurred 58% of the samples and no mutation has 
been found. Prasad et al. (2012) also reported that 
expression of bcl-2, p53 and loss of p16 expression 
are frequent and early events in POMM. bcl-2 
expression in the initial tumors was associated with 
significantly longer overall and disease specific 
survival. Bologna et al. (2013) evaluated the 
expression of integrins, claudins, and 
immunoglobulin-like adhesion molecules in oral 
mucosal melanomas and their association with 
clinical parameters. Positivity of integrin beta-3 and 
CD166 was associated with extensive vascular 
invasion and lower expression of CD54 was 
associated with cases with extensive necrosis. Most 
cases with metastatic disease were negative for 
CD66. Immunohistochemical results are shown in 
Figures 6 and 7. Hsieh et al. (2013) examined the 
central components of the CDKN2A and RAS-RAF-
MEK-ERK cascades by immunohistochemistry and 
found that the majority of the cases were positive for 
BRAF and ERK2. This pattern was associated with 
vascular invasion and metastasis. 
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Figure 5. Signaling pathways involved in mucosal melanoma pathogenesis. The binding of the ligand to the KIT results in 
activation of the MAPK and PI3K 
 
 
Cytogenetics 
Cytogenetics Morphological 
Genome-wide alterations in the number of copies of 
DNA and mutational status of BRAF and N-RAS in 
126 melanomas from four groups (30 melanomas 
from skin with chronic sun-induced damage and 40 
melanomas from skin without such damage; 36 
melanomas from palms, soles, and subungual (acral) 
sites; and 20 mucosal melanomas) were investigated. 
The results indicate that there are distinct genetic 
pathways in the development of melanoma and 
implicate CDK4 and CCND1 as independent 
oncogenes in melanomas without mutations in 
BRAF or N-RAS (Curtin et al., 2005). Comparative 
genomic hybridization performed in primary 
melanomas located on acral skin, mucosa, and skin 
with chronic sun-induced damage (CSD) revealed 
focal amplifications in chromosome 4q12.7, 
suggesting the involvement of c-KIT (Curtin et al., 
2006). Fluorescence in situ hybridization (FISH) 
was used to assess copy number changes of the 
cyclin D1 (CCND1), MDM2, c-myc (MYC), and 
HER2 genes in melanomas of melanomas of 
different location and different etiology. CCND1 
amplifications was  
found in 10% of the mucosal melanomas and MYC 
amplifications was found in 62.5% of the mucosal 
melanomas (Glatz-Krieger et al., 2006).  
Among the 23 acral and mucosal melanomas 
studied, copy number changes in GAB2 were found 
in 26% and KIT in 13% (3 of 23) of the cases. 
Mutations in BRAF were identified in 30% (7 of 23) 
of the cases and NRAS, in 4% (1 of 23) of the cases 
(Chernoff et al., 2009). 
Genes involved and 
proteins 
Genetic profiling of mucosal melanomas have 
identified a number of altered genes, such as KIT, 
BRAF and N-RAS, suggesting that molecular 
pathways like the mitogen‑activated protein kinase 
(MAPK) pathway (RAS/MEK/ERK) and the 
phosphotidylinositol-3-kinase-PTEN pathway 
(PI3K/AKT/PTEN/mTOR) might be used for 
potential targeted therapy.  
Unlike cutaneous melanoma, BRAF mutation are 
infrequent and KIT mutation seem to be frequently 
altered (Lopez et al., in press; Soma et al., 2014; Kerr 
et al 2012; Buery et al., 2011; Junkins-Hopkins, 
2010). 
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Figure 6. Primary oral mucosal melanoma: expression of CD166 surrounding the membrane of neoplastic melanocytes. 
(Immunohistochemistry, original magnification X400) 
 
 
 
 
 
Figure 7. Primary oral mucosal melanoma: a high expression of integrin beta 3 in a level III melanoma. Association with vascular 
invasion. (Immunohistochemistry, original magnification X250) 
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KIT 
Location 
4q12 
DNA / RNA 
This gene has 4 transcripts (splice variants). KIT-001 
has 21 coding exons and a transcript length of 5,186 
bps. KIT-002 has 21 coding exons and a transcript 
length of 3,470 bps. 
Protein 
Proteins with 976 and 972 amino acids residues. C-
KIT gene encodes a tyrosine kinase receptor for the 
stem cell factor. The mitogen-activated protein 
kinase (MAPK) pathway (RAS/MEK/ERK) and the 
phosphotidylinositol-3-kinase-PTEN pathway 
(PI3K/AKT/PTEN/mTOR) can be triggered by 
activation of c-kit. High expression of KIT protein is 
observed in mucosal melanomas frequently 
associated with gene mutation (Tacastacas et al., 
2014; Rivera et al., 2008). 
BRAF 
Location 
7q34 
DNA / RNA 
This gene has 5 transcripts (splice variants). BRAF-
001 has 18 coding exons and a transcript length of 
2,480 bps 
Protein 
Protein with 766 amino acids residues. BRAF is a 
serine-threonine kinase that once activated leads to 
activation of other kinases promoting cell survival. 
The evidence of BRAF mutation in mucosal 
melanomas is controversial, varying from 3 to 10% 
(Tacastacas et al., 2014; Buery et al., 2011; Cohen et 
al., 2004). 
NRAS 
Location 
1p13.2 
DNA / RNA 
This gene has 1 transcript (splice variant). NRAS-
001 has 7 coding exons and a transcript length of 
4,449 bps 
Protein 
Protein with 189 amino acids residues. NRAS is a 
GTPase involved in signaling transduction and 
control of cell growth (Tacastacas et al., 2014; Buery 
et al., 2011). 
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